The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
Open accessAbstract
Treatment with erythropoietin (epo) may improve the anemia of myelodysplastic syndromes (MDS) in approximately 20% of patients. Previous studies have suggested that treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and epo may increase this response rate. In the present phase II study, patients with MDS and anemia were randomized to treatment with G-CSF + epo according to one of two alternatives; arm A starting with G-CSF for 4 weeks followed by the combination for 12 weeks, and arm B starting with epo for 8 weeks followed by the combination for 10 weeks. Fifty evaluable patients (10 refractory anemia [RA], 13 refractory anemia with ring sideroblasts [RARS], and 27 refractory anemia with excess blasts [RAEB]) were included in the study, three were evaluable only for epo as monotherapy and 47 for the combined treatment. The overall response rate to G-CSF + epo was 38%, which is identical to that in our previous study. The response rates for patients with RA, RARS, and RAEB were 20%, 46%, and 37%, respectively. Response rates were identical in the two treatment groups indicating that an initial treatment with G-CSF was not neccessary for a response to the combination. Nine patients in arm B showed a response to the combined treatment, but only three of these responded to epo alone. This suggests a synergistic effect in vivo by G-CSF + epo. A long-term follow-up was made on 71 evaluable patients from both the present and the preceding Scandinavian study on G-CSF + epo. Median survival was 26 months, and the overall risk of leukemic transformation during a median follow-up of 43 months was 28%. Twenty patients entered long-term maintenance treatment and showed a median duration of response of 24 months.The international prognostic scoring system (IPSS) was effective to predict survival, leukemic transformation, and to a lesser extent, duration of response, but had no impact on primary response rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Vadhan-Raj, S., Keating, M., LeMaistre, A., Hittelman, W. N., McCredie, K., Trujillo, J. M., Broxmeyer, H. E., Henney, C., & Gutterman, J. U. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712173172501 · Cited by 624
Hematology: Basic Principles and Practice
Peterson, L. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.3.354a · Cited by 504
Hellström‐Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., ÖSt, Å., & Greenberg, P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4013211.x · Cited by 312
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
Cazzola, M., Mercuriali, F., & Brugnara, C. (1997) · Blood · doi:10.1182/blood.v89.12.4248 · Cited by 262
Negrin, R., Haeuber, D., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., & Greenberg, P. (1990) · Blood · doi:10.1182/blood.v76.1.36.36 · Cited by 232
Beguin, Y., Clemons, G., Pootrakul, P., & Fillet, G. (1993) · Blood · doi:10.1182/blood.v81.4.1067.1067 · Cited by 227
Self-citationGalton, D. A. (1989) · BMJ · doi:10.1136/bmj.299.6699.582 · Cited by 206
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1993) · Annals of Hematology · doi:10.1007/bf01697631 · Cited by 114
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Valent, P., Horny, H.-P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.-J., Krieger, O., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.009 · Cited by 513
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04153.x · Cited by 458
Self-citationSoluble transferrin receptor for the evaluation of erythropoiesis and iron status
Beguin, Y. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00005-6 · Cited by 454
Self-citation
Metadata
- Authors
- Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.-M., Winqvist, I., Öberg, G., Österborg, A., & Öst, Å.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 68-75
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1541533982
- Cited by
- 304
- References
- 15
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients. https://app.cochat.ai/papers/10.1182/blood.v92.1.68.413k23_68_75
- The paper
- Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.-M., Winqvist, I., Öberg, G., Österborg, A., & Öst, Å. (1998). Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients. Blood. https://doi.org/10.1182/blood.v92.1.68.413k23_68_75
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.